Brammer Bio in talks to build manufacturing site in Massachusetts

The US cell and gene therapy CDMO expects to employ around 300 people at the plant by 2021

Photo as seen on company website

Brammer Bio is looking to build a pharma manufacturing facility in Norton, US. The viral vector manufacturers are attempting to finance this Massachusetts plant with tax increment financing (TIF).

Town Manager Michael Yunits told The Sun Chronicle that details of the TIF are still being worked out, however, there is a meeting of residents to ask for a TIF agreement scheduled for late August.

The US CDMO provides services for the cell and gene therapy sector and expects to employ around 300 people in the town by 2021.

Ron O’Brien, a spokesman for Thermo Fisher who purchased Brammer Bio in March, told FiercePharmaManufacturing that the project is still in a preliminary stage and additional information such as size and projected cost will be released in the near future.

This is not the first major project in the area. In 2016, Alnylam Pharmaceuticals built a US$200 million, 200,000 sqft facility in Norton’s industrial park near Taunton.

Companies